Stock Rich List
#5914 on the rich list of 14,644 insiders

Christopher Gibson

Director at Recursion Pharmaceuticals; Director at Pacific Biosciences of California. Based in Salt Lake City, Utah.

$16.7M
in disclosed stock, −$645K (−3.72%) today
Market closed. Prices as of Nov 19, 4:00 PM ET
Rank
5914th of 14,644
Companies held
2
Largest holding
RXRX, 98.8% of total
Latest SEC filing
Jun 5, 2026

What the $16.7M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Recursion Pharmaceuticals RXRX
Class B Common Stock
Directly4,263,334$2.72$11.6M69.4%Form 4, Jun 5, 2026
Recursion Pharmaceuticals RXRX
Class A Common Stock
Directly883,735$2.72$2.4M14.4%Form 4, Jun 5, 2026
Recursion Pharmaceuticals RXRX
Class B Common Stock
Through LAHWRAN-4 LLC388,000$2.72$1.1M6.3%Form 4, Jun 5, 2026
Recursion Pharmaceuticals RXRX
Class B Common Stock
Through LAHWRAN-3 LLC386,000$2.72$1.0M6.3%Form 4, Jun 5, 2026
Recursion Pharmaceuticals RXRX
Class A Common Stock
Through Gibson Family Trust100,000$2.72$272K1.6%Form 4, Aug 11, 2025
Pacific Biosciences of California PACB
Common Stock
Directly111,386$1.76$196K1.2%Form 4, Apr 8, 2026
Recursion Pharmaceuticals RXRX
Class B Common Stock
Through Gibson Family Trust50,000$2.72$136K0.8%Form 4, Jun 5, 2026

Share counts are the amounts Christopher Gibson reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Jun 5, 2026SoldRXRX40,000$3.62$145KView
May 22, 2026SoldRXRX40,000$3.08$123KView
May 7, 2026SoldRXRX40,000$3.37$135KView
Apr 22, 2026SoldRXRX40,000$3.61$144KView
Apr 7, 2026SoldRXRX40,000$3.10$124KView
Mar 23, 2026SoldRXRX40,000$3.25$130KView
Feb 19, 2026SoldRXRX40,000$3.46$138KView
Feb 4, 2026SoldRXRX40,000$4.12$165KView
Jan 20, 2026SoldRXRX40,000$4.47$179KView
Jan 5, 2026SoldRXRX40,000$4.25$170KView
Dec 19, 2025SoldRXRX40,000$4.50$180KView
Dec 4, 2025SoldRXRX40,000$4.63$185KView
Nov 19, 2025SoldRXRX40,000$4.16$166KView
Nov 4, 2025SoldRXRX40,000$5.21$208KView
Oct 23, 2025SoldRXRX100,000$5.70$570KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
5911Jeffrey M. Farber
Executive Vice President, The Hanover Insurance Group. Worcester, MA
$16.7M−$137K (−0.81%)
5912Levien Meredith A. Kopit
PRESIDENT & CEO, The New York Times. San Francisco, CA
$16.7M−$413K (−2.41%)
5913Jennifer K. Mann
Executive Vice President, The Coca-Cola. Atlanta, GA
$16.7M−$346K (−2.03%)
5914Christopher Gibson
Director, Recursion Pharmaceuticals. Salt Lake City, UT
$16.7M−$645K (−3.72%)
5915Mark Vergnano
Director, The Chemours. Milwaukee, WI
$16.7M−$380K (−2.22%)
5916Frank T. Connor
Executive Vice President & CFO, Textron. New York, NY
$16.7M−$367K (−2.15%)
5917Ronald Blake Chatelain
See Remarks, Red River Bancshares. Alexandria, LA
$16.7M−$103K (−0.61%)

Other Recursion Pharmaceuticals insiders

All RXRX insiders

Questions

How much stock does Christopher Gibson own?

Christopher Gibson holds $16,709,347 in listed stock based on SEC filings and current prices, mostly Recursion Pharmaceuticals (RXRX). That ranks 5914th on the Stock Rich List.

Is this Christopher Gibson's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Christopher Gibson last buy or sell stock?

The most recent open-market trade on file is a sale of 40,000 RXRX shares on Jun 5, 2026 at $3.62.